|
Module home
Module introduction
Pre-module test
Module information
About the author
Section 1: Treatment of
antidepressant-induced sexual dysfunction
(1.1) Section 1: Treatment of antidepressant-induced sexual
dysfunction
(1.2) Before you begin
(1.3) A woman who thought she was 'frigid'
(1.4) A woman who thought she was 'frigid': comment
(1.5) Reflection
(1.6) Reflection: suggested answers
(1.7) Reflection
(1.8) Reflection: suggested answers
(1.9) Overview of treatment strategies
(1.10) Modification of the current antidepressive treatment
(1.11) Treatment of sexual dysfunction targeting specific
receptors
(1.12) Other treatments
(1.13) Reflection
(1.14) Pharmacological reversal – target
noradrenaline
(1.15) Target: noradrenaline
(1.16) Outlook: autoreceptors
(1.17) Reflection
(1.18) Pharmacological reversal – target
serotonin
(1.19) Target: serotonin
(1.20) Reflection
(1.21) Pharmacological reversal – target
dopamine
(1.22) Target: dopamine
(1.23) Reflection
(1.24) Pharmacological reversal – other
targets
(1.25) Other targets
(1.27) Pharmacological reversal – target nitric
oxide (NO)
(1.28) It all starts with nitric oxide…
(1.29) PD5-inhibitors: contraindications
(1.30) Yet another story...
(1.31) Female HSDD revisited – on the hunt for a ‘pink
Viagra’...
(1.32) Section 1: Recap
(1.33) Section 1:
Summary
Section 2: Other treatments for
sexual dysfunction
(2.1) Section 2: Other treatments for sexual dysfunction
(2.2) Reflection
(2.3) Reflection: suggested answers
(2.4) Hormone treatments for women
(2.5) Why has HRT fallen out of favour with women?
(2.6) Hormone treatments for women – potential side
effects
(2.7) Reflection
(2.8) Reflection: suggested answers
(2.9) Hormone treatments for men
(2.10) Outlook
(2.11) Reflection
(2.12) Reflection: suggested answers
(2.13) Complementary medicines for sexual dysfunction
(2.14) Recommending complementary medicines: issues
(2.15) Hypomanic episodes
(2.16) LavigraTM
(2.17) ArginMax
(2.18) ProvestraTM
(2.19) Outlook
(2.20) Section 2: Recap
(2.21) Section 2:
Summary
Section 3: Formal aspects of
prescribing for sexual dysfunction
(3.1) Section 3: Formal aspects of prescribing for sexual
dysfunction
(3.2) Prescribing unlicensed medications: recommendations
(3.3) The GMC requirements for prescribing unlicensed
medications
(3.4) The GMC requirements for prescribing a medicine for use
outside the terms of its licence
(3.5) Informed consent
(3.6) The criteria for informed consent: quick recap
(3.7) Reimbursement for treatments
(3.8) The BNF requirements for prescribing for erectile
dysfunction
(3.9) The severe distress clause
(3.10) Section 3: Recap
(3.11) Section 3:
Summary
Module summary
Conclusions
Module test
Take-home notes
References
Further reading
Acknowledgements
Send feedback
Annual
revisions
Annual revisions
|